Glucagon Counter-Regulation to Hypoglycemia During Incretin-Based Therapy
Incretin-based therapy is associated with low risk of hypoglycemia in type 2 diabetes mellitus (T2DM) possibly due to its glucose-dependency in stimulating insulin secretion and a sustained glucagon response during hypoglycemia. This is of special relevance when it is combined with insulin or given to elderly patients since both insulin therapy and high age are associated with impaired glucagon co